PE20081199A1 - Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa - Google Patents
Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasaInfo
- Publication number
- PE20081199A1 PE20081199A1 PE2007001699A PE2007001699A PE20081199A1 PE 20081199 A1 PE20081199 A1 PE 20081199A1 PE 2007001699 A PE2007001699 A PE 2007001699A PE 2007001699 A PE2007001699 A PE 2007001699A PE 20081199 A1 PE20081199 A1 PE 20081199A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- azacicloalkanes
- desaturase
- coenzyme
- delta
- Prior art date
Links
- 108010087894 Fatty acid desaturases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102100034543 Fatty acid desaturase 3 Human genes 0.000 title 1
- 239000005515 coenzyme Substances 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 2
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical compound O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE AZACICLOALCANOS DE FORMULA (I) DONDE q ES 0 O 1; r ES 0 O 1; X-Y ES N-C(O), N-CRaRb, CR14-O, ENTRE OTROS, EN DONDE Ra Y Rb SON CADA UNO H O ALQUILO(C1-C3) OPCIONALMENTE SUSTITUIDO CON F O HIDROXI; R14 ES H O ALQUILO(C1-C3); W ES UN HETEROARILO SELECCIONADO DE (a), (b), ENTRE OTROS, EN DONDE R1 ES HETEROARILO DE FORMULA (i), (ii), ENTRE OTROS, DONDE Rc ES -(CH2)mCO2H, -(CH2)mCO2ALQUILO(C1-C3), ENTRE OTROS; m ES DE 0 A 4; R5, R6, R7, R8, R9, R10, R11 Y R12 SON CADA UNO H, F O ALQUILO(C1-C3) OPCIONALMENTE SUSTITUIDO CON F O HIDROXI; Ar ES FENILO, NAFTILO O HETEROARILO OPCIONALMENTE SUSTITUIDO CON R3, DONDE R3 ES ALQUILO(C1-C6), HALOGENO, NITRO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO[5-(5-{4-[2-(TRIFLUOROMETIL)FENOXI]PIPERIDIN-1-IL}-1,3,4-TIADIAZOL-2-IL)-2H-TETRAZOL-2-IL]ACETICO, ACIDO[5-(5-{4-[2-(TRIFLUOROMETIL)FENOXI]PIPERIDIN-1-IL}-1,3,4-TIADIAZOL-2-IL)-1H-TETRAZOL-1-IL]ACETICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE ESTEAROIL-COENZIMA A DELTA-9-DESATURASA (SCD) SIENDO UTILES EN EL TRATAMIENTO DE ATEROSCLEROSIS, OBESIDAD, DIABETES DE TIPO 2, SINDROME METABOLICO, RESISTENCIA A INSULINA, CANCER, ESTEATOSIS HEPATICA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87221606P | 2006-12-01 | 2006-12-01 | |
| US89890007P | 2007-02-01 | 2007-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081199A1 true PE20081199A1 (es) | 2008-10-19 |
Family
ID=39467388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001699A PE20081199A1 (es) | 2006-12-01 | 2007-11-30 | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8063224B2 (es) |
| EP (1) | EP2099793B1 (es) |
| JP (1) | JP5050061B2 (es) |
| KR (1) | KR20090086623A (es) |
| AR (1) | AR064026A1 (es) |
| AT (1) | ATE543816T1 (es) |
| AU (1) | AU2007327276B2 (es) |
| BR (1) | BRPI0719702A2 (es) |
| CA (1) | CA2670703C (es) |
| CL (1) | CL2007003440A1 (es) |
| CO (1) | CO6190521A2 (es) |
| CR (1) | CR10858A (es) |
| EA (1) | EA200970524A1 (es) |
| EC (1) | ECSP099375A (es) |
| GT (1) | GT200900144A (es) |
| IL (1) | IL198824A0 (es) |
| MA (1) | MA31017B1 (es) |
| MX (1) | MX2009005713A (es) |
| NO (1) | NO20092469L (es) |
| PE (1) | PE20081199A1 (es) |
| SV (1) | SV2009003275A (es) |
| TN (1) | TN2009000212A1 (es) |
| TW (1) | TW200826936A (es) |
| WO (1) | WO2008064474A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4722801A (en) * | 2000-02-24 | 2001-09-03 | Xenon Genetics Inc | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
| WO2007134457A1 (en) * | 2006-05-22 | 2007-11-29 | Merck Frosst Canada Ltd. | Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2007143823A1 (en) * | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2654098A1 (en) | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2660114A1 (en) * | 2006-08-09 | 2008-02-14 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| EP2148878A4 (en) * | 2007-04-20 | 2011-08-10 | Merck Canada Inc | NEW HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| WO2008141455A1 (en) * | 2007-05-23 | 2008-11-27 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US7842696B2 (en) | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| PE20090882A1 (es) * | 2007-07-19 | 2009-08-03 | Takeda Pharmaceutical | Preparacion solida que comprende alogliptina y clorhidrato de metformina |
| AU2008280784A1 (en) * | 2007-07-20 | 2009-01-29 | Merck Frosst Canada Ltd | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2012501975A (ja) * | 2008-09-08 | 2012-01-26 | メルク カナダ インコーポレイテッド | ステアロイルコエンザイムＡδ−９デサチュラーゼの阻害剤としての芳香族複素環化合物 |
| JP5597210B2 (ja) * | 2009-02-17 | 2014-10-01 | メルク カナダ インコーポレイテッド | ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤として有用な新規スピロ化合物 |
| CA2750635A1 (en) * | 2009-02-23 | 2010-08-26 | Merck Canada Inc. | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US20120010186A1 (en) * | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2011011872A1 (en) | 2009-07-28 | 2011-02-03 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| KR20130100903A (ko) | 2010-04-28 | 2013-09-12 | 바이엘 크롭사이언스 아게 | 살진균제로서의 케토헤테로아릴피페리딘 및 케토헤테로아릴피페라진 유도체 |
| EA027351B1 (ru) * | 2011-01-28 | 2017-07-31 | 4-Эс-Си Дискавери Гмбх | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления |
| RU2014119426A (ru) | 2011-10-15 | 2015-11-20 | Дженентек, Инк. | Способы применения антагонистов scd1 |
| WO2013062882A1 (en) * | 2011-10-26 | 2013-05-02 | Merck Canada Inc. | Scd inhibitors for the treatment of hcv |
| WO2013134546A1 (en) | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2013175474A2 (en) | 2012-05-22 | 2013-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Selective inhibitors of undifferentiated cells |
| EP3177292B1 (en) | 2014-08-07 | 2020-11-25 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| WO2018081167A1 (en) | 2016-10-24 | 2018-05-03 | Yumanity Therapeutics | Compounds and uses thereof |
| IL304017A (en) | 2017-01-06 | 2023-08-01 | Yumanity Therapeutics Inc | Methods for treating neurological disorders |
| EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
| SG11202009280RA (en) | 2018-03-23 | 2020-10-29 | Yumanity Therapeutics Inc | Compounds and uses thereof |
| SG11202108079RA (en) | 2019-01-24 | 2021-08-30 | Yumanity Therapeutics Inc | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1595923A1 (de) * | 1965-02-20 | 1969-11-27 | Merck Ag E | 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung |
| ES2162235T3 (es) | 1996-01-15 | 2001-12-16 | Janssen Pharmaceutica Nv | Piridazinaminas inhibidoras de la angiogenesis. |
| US20050119251A1 (en) | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
| US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| EP1651616B1 (en) | 2003-07-30 | 2012-05-02 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7345043B2 (en) | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| EP1804792A1 (en) | 2004-09-20 | 2007-07-11 | Xenon Pharmaceuticals Inc. | Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd) |
| AR051026A1 (es) * | 2004-09-20 | 2006-12-13 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| AU2005286728A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| WO2006034341A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| BRPI0515505A (pt) * | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase |
| MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| CA2580857A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| GT200600046A (es) | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
| WO2006125181A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their use as stearoyl-coa desaturase modulators |
| EP1902051A1 (en) | 2005-06-09 | 2008-03-26 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AU2006272334A1 (en) | 2005-07-20 | 2007-01-25 | Merck Frosst Canada Ltd | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| WO2007038865A1 (en) | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd. | Substituted quinolines as inhibitors of leukotriene biosynthesis |
| AU2006315025A1 (en) | 2005-11-15 | 2007-05-24 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP1966183A4 (en) | 2005-12-20 | 2010-12-29 | Merck Frosst Canada Ltd | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE |
| WO2007134457A1 (en) | 2006-05-22 | 2007-11-29 | Merck Frosst Canada Ltd. | Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2007143823A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2654098A1 (en) | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2660114A1 (en) | 2006-08-09 | 2008-02-14 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US20100004245A1 (en) | 2006-10-20 | 2010-01-07 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AR064965A1 (es) | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
-
2007
- 2007-11-26 TW TW096144835A patent/TW200826936A/zh unknown
- 2007-11-28 AT AT07845603T patent/ATE543816T1/de active
- 2007-11-28 WO PCT/CA2007/002139 patent/WO2008064474A1/en not_active Ceased
- 2007-11-28 JP JP2009538560A patent/JP5050061B2/ja not_active Expired - Fee Related
- 2007-11-28 EP EP07845603A patent/EP2099793B1/en active Active
- 2007-11-28 KR KR1020097013826A patent/KR20090086623A/ko not_active Ceased
- 2007-11-28 MX MX2009005713A patent/MX2009005713A/es unknown
- 2007-11-28 BR BRPI0719702-0A patent/BRPI0719702A2/pt not_active IP Right Cessation
- 2007-11-28 CA CA2670703A patent/CA2670703C/en not_active Expired - Fee Related
- 2007-11-28 AU AU2007327276A patent/AU2007327276B2/en not_active Ceased
- 2007-11-28 EA EA200970524A patent/EA200970524A1/ru unknown
- 2007-11-29 CL CL200703440A patent/CL2007003440A1/es unknown
- 2007-11-29 AR ARP070105302A patent/AR064026A1/es not_active Application Discontinuation
- 2007-11-30 US US11/998,501 patent/US8063224B2/en active Active
- 2007-11-30 PE PE2007001699A patent/PE20081199A1/es not_active Application Discontinuation
-
2009
- 2009-05-19 IL IL198824A patent/IL198824A0/en unknown
- 2009-05-27 SV SV2009003275A patent/SV2009003275A/es unknown
- 2009-05-27 GT GT200900144A patent/GT200900144A/es unknown
- 2009-05-28 CO CO09054946A patent/CO6190521A2/es not_active Application Discontinuation
- 2009-05-29 TN TNP2009000212A patent/TN2009000212A1/fr unknown
- 2009-06-01 EC EC2009009375A patent/ECSP099375A/es unknown
- 2009-06-10 CR CR10858A patent/CR10858A/es unknown
- 2009-06-22 MA MA32023A patent/MA31017B1/fr unknown
- 2009-06-30 NO NO20092469A patent/NO20092469L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200826936A (en) | 2008-07-01 |
| TN2009000212A1 (en) | 2010-10-18 |
| MA31017B1 (fr) | 2009-12-01 |
| IL198824A0 (en) | 2010-02-17 |
| JP2010510993A (ja) | 2010-04-08 |
| GT200900144A (es) | 2011-06-23 |
| CL2007003440A1 (es) | 2008-04-04 |
| WO2008064474A1 (en) | 2008-06-05 |
| ECSP099375A (es) | 2009-07-31 |
| KR20090086623A (ko) | 2009-08-13 |
| EA200970524A1 (ru) | 2009-12-30 |
| JP5050061B2 (ja) | 2012-10-17 |
| SV2009003275A (es) | 2009-11-18 |
| CA2670703A1 (en) | 2008-06-05 |
| EP2099793A4 (en) | 2010-12-29 |
| CA2670703C (en) | 2012-05-15 |
| CO6190521A2 (es) | 2010-08-19 |
| ATE543816T1 (de) | 2012-02-15 |
| EP2099793B1 (en) | 2012-02-01 |
| AU2007327276B2 (en) | 2011-06-09 |
| EP2099793A1 (en) | 2009-09-16 |
| MX2009005713A (es) | 2009-06-08 |
| AR064026A1 (es) | 2009-03-04 |
| US8063224B2 (en) | 2011-11-22 |
| NO20092469L (no) | 2009-08-27 |
| AU2007327276A1 (en) | 2008-06-05 |
| US20080132542A1 (en) | 2008-06-05 |
| CR10858A (es) | 2009-06-25 |
| BRPI0719702A2 (pt) | 2013-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081199A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
| PE20081398A1 (es) | Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1) | |
| PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
| PE20141375A1 (es) | Activadores de glucoquinasa | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| PE20090815A1 (es) | Compuesto de amida | |
| PE20050018A1 (es) | Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b) | |
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| PE20081532A1 (es) | Compuestos novedosos | |
| PE20110906A1 (es) | Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif | |
| PE20090290A1 (es) | Derivados de pirrolopiridina como inhibidores de bace | |
| PE20091527A1 (es) | Derivados de piridazinona | |
| PE20090150A1 (es) | Compuestos derivados de oxadiazol | |
| PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| PE20080360A1 (es) | Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3 | |
| PE20090904A1 (es) | ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b | |
| PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
| MXPA05008600A (es) | Compuestos para el tratamiento de desordenes metabolicos. | |
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| DE602005023343D1 (de) | Pyrimidinderivate als gpcr-agonisten | |
| PE20091339A1 (es) | Derivados de oxadiazol con actividad sobre receptores s1p1 | |
| PE20081353A1 (es) | Compuestos del inhibidor de fosfoinositida 3-cinasa | |
| PE20080925A1 (es) | DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA) | |
| PE20060427A1 (es) | Derivados de pirazol como inhibidores de la union del glucagon y composiciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |